Acthar

Mallinckrodt Rips Higher After Company Confirms $1.6B Opioid Litigation Settlement

Mallinckrodt Agrees To Pay $15.4M In DOJ Settlement Over Acthar Subsidies

Mallinckrodt Shares Fall 25%: What You Need To Know

Mallinckrodt Agrees To Pay $15.4M In DOJ Settlement Over Acthar Subsidies

Mallinckrodt Shares Fall 25%: What You Need To Know

Canaccord Turns Bullish On Mallinckrodt: 4 Reasons Why

Barclays: Mallinckrodt's Sucampo Deal Overshadowed By Competitive Threats

Canaccord Turns Bullish On Mallinckrodt: 4 Reasons Why

Barclays: Mallinckrodt's Sucampo Deal Overshadowed By Competitive Threats

Analyst: Mallinckrodt Investors Seem To Be Pricing In Extreme Issues For Acthar

Oppenheimer Suggests Buying Mallinckrodt On FTC Investigation Inspired Weakness

Acthar Recent News

Andrew Left Challenges Mallinckrodt, Compares Acthar To The EpiPen

Andrew Left Talked Mallinckrodt And Evergrande On Bloomberg This Morning

Allegations Mallinckrodt Is Hiking Acthar Prices Called 'False'

Oppenheimer Calls Mallinckrodt's New Acthar Data 'Impressive,' Despite This Week's Turmoil

Northland Starts Jazz Pharma, Mallinckrodt, Shire With Outperform Ratings

Benzinga Mid-Day Market Update

Questcor Plummets After Aetna Limits Coverage of Company Drug